Annuncio pubblicitario
Italia Markets close in 3 hrs 4 mins
  • FTSE MIB

    34.708,10
    +368,78 (+1,07%)
     
  • Dow Jones

    39.387,76
    +331,36 (+0,85%)
     
  • Nasdaq

    16.346,26
    +43,46 (+0,27%)
     
  • Nikkei 225

    38.229,11
    +155,13 (+0,41%)
     
  • Petrolio

    79,80
    +0,54 (+0,68%)
     
  • BTC-EUR

    58.599,07
    +1.855,87 (+3,27%)
     
  • CMC Crypto 200

    1.309,70
    -48,31 (-3,56%)
     
  • Oro

    2.381,00
    +40,70 (+1,74%)
     
  • EUR/USD

    1,0784
    0,0000 (-0,0000%)
     
  • S&P 500

    5.214,08
    +26,41 (+0,51%)
     
  • HANG SENG

    18.963,68
    +425,87 (+2,30%)
     
  • Euro Stoxx 50

    5.091,44
    +37,03 (+0,73%)
     
  • EUR/GBP

    0,8603
    -0,0005 (-0,06%)
     
  • EUR/CHF

    0,9778
    +0,0014 (+0,14%)
     
  • EUR/CAD

    1,4745
    +0,0001 (+0,01%)
     

TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

TG Therapeutics, Inc.
TG Therapeutics, Inc.

Fireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Bank of America Securities 2023 Health Care Conference, being held at the Encore Hotel, in Las Vegas, NV on Tuesday May 9th through Thursday May 11th, 2023. The fireside chat is scheduled to take place on Tuesday, May 9, 2023, at 3:00 PM PT.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ANNUNCIO PUBBLICITARIO

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6